市場調査レポート

商品コード

ヒトマイクロバイオーム市場の2030年までの予測：製品別、疾患別、タイプ別、用途別、地域別の世界分析

Human Microbiome Market Forecasts to 2030 - Global Analysis By Product (Medical Foods, Prebiotics, Probiotics, Symboitics and Other Products), Disease, Type, Application and By Geography

出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 595,815円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 753,742円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 911,669円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,076,775円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のヒトマイクロバイオーム市場は2023年に8億米ドルを占め、予測期間中のCAGRは34.1％で成長し、2030年には63億米ドルに達すると予測されています。

「ヒトマイクロバイオーム市場」という用語は、ヒトマイクロバイオームの徹底的な研究、分析、商業的応用に焦点を当てたバイオテクノロジーと医療の分野を定義しています。人体とそこに生息する微生物との共生的相互作用を理解するために、研究、診断、治療、オーダーメイド医療など、さまざまな分野から構成されています。

米国がん協会（American Cancer Society）によると、2022年には米国で新たに約191万8,030人のがん患者が報告されると推定されています。さらに、Globocan 2020の統計によると、がんの新規症例数は274,364件で、2040年までに40万564件に達すると予想されています。

マイクロバイオーム研究の進歩

過去数十年にわたりマイクロバイオームの調査が大幅に進歩した結果、ヒトの健康と疾病へのマイクロバイオームの関与に関する理解に大きな変化が生じています。さらに、ハイスループット配列決定法と強力なバイオインフォマティクス・ツールのおかげで、ヒトの体内に存在する微生物の膨大なコミュニティーが徹底的に分析され、特徴付けられるようになっています。

規制の壁

微生物ベースの製品や治療法に対する透明で統一された規制プロセスの欠如は、主な問題のひとつです。微生物ベースの製品や治療法に対するシンプルで統一された規制の枠組みがないため、市場の拡大が制限され、参入のハードルが高くなる可能性があります。しかし、微生物群集の多様性とヒトマイクロバイオームの動的な性質は、製品の安全性と有効性を評価する際に規制当局に困難をもたらします。

慢性疾患の流行は増加傾向にある

世界的に、肥満、糖尿病、炎症性腸疾患、自己免疫疾患などの慢性疾患が蔓延しつつあります。その結果、これらの慢性疾患をよりよく理解し管理するために、医療関係者や学識経験者は微生物に基づく療法を模索しています。さらに、慢性疾患を抱える人々の微生物バランスを回復させるためには、プロバイオティクス、糞便微生物叢移植（FMT）、マイクロバイオーム制御など、多くの開発手法が関与しています。

研究開発費

ヒトマイクロバイオームの複雑さを完全に理解し、それに基づいた製品や排除を開発するためには、マイクロバイオーム研究の分野では研究開発（R&D）に多額の投資が必要です。プロバイオティクスやプレバイオティクスのようなマイクロバイオーム治療法の開発、データ解析、臨床試験、マイクロバイオームシークエンシングなどは、すべてこれらの支出に含まれます。しかし、利用可能な製品や治療法の多様性は、研究開発費の高さによって阻害され、中小企業や新興企業の市場参入を妨げている可能性があります。

COVID-19の影響：

臨床試験研究は、COVID-19の流行によって世界的に大きな支障をきたしています。通常、研究にはCOVID-19への曝露によって最も危険にさらされる貧困層が含まれることを考えると、これは非常に重要なことです。同様に、COVID-19は微生物ベースの医薬品や診断機器の前臨床研究や臨床試験など、他の企業の経営にも悪影響を及ぼしており、現在も及ぼしている可能性があります。

プロバイオティクス分野は予測期間中最大となる見込み

プロバイオティクス分野は予測期間中最大になると予想されます。プロバイオティクスは生きた微生物であり、宿主に十分な割合で投与されると、腸内細菌叢を回復または維持することによって宿主の全体的な健康を改善または維持します。免疫の健康を促進し、消化を促進し、一般的な健康状態のさまざまな要素に影響を与える可能性があることから、非常に人気が高まっています。さらに、予防的な健康とウェルネスが重視されるようになったことで、顧客が医療上の問題に対する微生物に優しい治療法を探すようになり、プロバイオティクス分野は発展すると予想されます。

診断分野は予測期間中に最も高いCAGRを示すと予想されます。

健康と病気においてヒトマイクロバイオームが果たす重要な役割に対する認識が高まっていることから、診断分野は予測期間を通じて最も高い成長率を示すと予想されます。マイクロバイオーム診断薬は、シーケンシング技術とバイオインフォマティクスの発展により、体内の微生物集団をより深く理解することができ、個別化された正確な治療を可能にします。さらに、マイクロバイオーム診断薬は、疾患の早期発見をサポートし、個別化された治療戦略を導き、介入の成功を評価する可能性があるため、医療でも普及しつつあります。

最大のシェアを占める地域

北米が最大のシェアを占めたのは、医療施設のネットワークが確立されていること、より高度な技術開発への大手企業の投資が拡大していること、新薬の開発プロセスが加速していること、この分野の研究開発が活発化していることなどが背景にあります。さらに、ヒトマイクロバイオーム治療が注目され、生活習慣病が蔓延し、次世代シーケンシングとヒトマイクロバイオームの技術的進歩が進んでいます。これらの要因はすべて、この地域における市場の成長に寄与しています。

CAGRが最も高い地域：

プロバイオティクス、プレバイオティクス、マイクロバイオーム関連製品に対する消費者の関心が高まっていることから、アジア太平洋は収益性の高い成長を遂げると予測されます。これは、消化、栄養的ウェルネス、全体的なウェルビーイングにおけるマイクロバイオームの重要性が広く認識されつつあるためです。さらに、アジア太平洋では、マイクロバイオーム科学分野の研究開発活動が活発化しており、特に中国、日本、韓国など、バイオテクノロジーやライフサイエンスに多額の投資を行っている国々で顕著です。

2022年5月、がん、喘息、自閉症、関節炎などの自己免疫疾患などの疾患に対するバイオ治療製品を開発する世界的製薬企業である4Dファーマは、尿路上皮がんの治療を適応とするPD-L1遮断抗体であるバベンチオを併用したMRx0518の臨床試験を発表しました。

無料カスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場参入企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

イントロダクション
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東およびアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東およびアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Seres Therapeutics
Second Genome Inc.
Osel Inc.
Exeliom Biosciences SAS
Ginkgo Bioworks
Finch Therapeutics Group Inc.
Evelo Biosciences Inc
DuPont
Axial Biotherapeutics, Inc.
Astarte Medical

図表

List of Tables

Table 1 Global Human Microbiome Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 4 Global Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 5 Global Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 6 Global Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 7 Global Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 8 Global Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 9 Global Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 10 Global Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 11 Global Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 12 Global Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 13 Global Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 14 Global Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 15 Global Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 16 Global Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 17 Global Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 18 Global Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 19 Global Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 20 Global Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 21 Global Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
Table 22 North America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
Table 23 North America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 24 North America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 25 North America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 26 North America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 27 North America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 28 North America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 29 North America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 30 North America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 31 North America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 32 North America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 33 North America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 34 North America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 35 North America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 36 North America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 37 North America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 38 North America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 39 North America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 40 North America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 41 North America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 42 North America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
Table 43 Europe Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
Table 44 Europe Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 45 Europe Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 46 Europe Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 47 Europe Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 48 Europe Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 49 Europe Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 50 Europe Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 51 Europe Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 52 Europe Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 53 Europe Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 54 Europe Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 55 Europe Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 56 Europe Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 57 Europe Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 58 Europe Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 59 Europe Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 60 Europe Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 61 Europe Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 62 Europe Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 63 Europe Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
Table 64 Asia Pacific Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
Table 65 Asia Pacific Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 66 Asia Pacific Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 67 Asia Pacific Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 68 Asia Pacific Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 69 Asia Pacific Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 70 Asia Pacific Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 71 Asia Pacific Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 72 Asia Pacific Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 73 Asia Pacific Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 74 Asia Pacific Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 75 Asia Pacific Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 76 Asia Pacific Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 77 Asia Pacific Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 78 Asia Pacific Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 79 Asia Pacific Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 80 Asia Pacific Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 81 Asia Pacific Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 82 Asia Pacific Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 83 Asia Pacific Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 84 Asia Pacific Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
Table 85 South America Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
Table 86 South America Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 87 South America Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 88 South America Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 89 South America Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 90 South America Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 91 South America Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 92 South America Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 93 South America Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 94 South America Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 95 South America Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 96 South America Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 97 South America Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 98 South America Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 99 South America Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 100 South America Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 101 South America Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 102 South America Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 103 South America Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 104 South America Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 105 South America Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)
Table 106 Middle East & Africa Human Microbiome Market Outlook, By Country (2021-2030) ($MN)
Table 107 Middle East & Africa Human Microbiome Market Outlook, By Product (2021-2030) ($MN)
Table 108 Middle East & Africa Human Microbiome Market Outlook, By Medical Foods (2021-2030) ($MN)
Table 109 Middle East & Africa Human Microbiome Market Outlook, By Prebiotics (2021-2030) ($MN)
Table 110 Middle East & Africa Human Microbiome Market Outlook, By Probiotics (2021-2030) ($MN)
Table 111 Middle East & Africa Human Microbiome Market Outlook, By Symboitics (2021-2030) ($MN)
Table 112 Middle East & Africa Human Microbiome Market Outlook, By Other Products (2021-2030) ($MN)
Table 113 Middle East & Africa Human Microbiome Market Outlook, By Disease (2021-2030) ($MN)
Table 114 Middle East & Africa Human Microbiome Market Outlook, By Metabolic (2021-2030) ($MN)
Table 115 Middle East & Africa Human Microbiome Market Outlook, By Endocrine (2021-2030) ($MN)
Table 116 Middle East & Africa Human Microbiome Market Outlook, By Infectious (2021-2030) ($MN)
Table 117 Middle East & Africa Human Microbiome Market Outlook, By Type (2021-2030) ($MN)
Table 118 Middle East & Africa Human Microbiome Market Outlook, By Cancer (2021-2030) ($MN)
Table 119 Middle East & Africa Human Microbiome Market Outlook, By Metabolic and Gastrointestinal Disorders (2021-2030) ($MN)
Table 120 Middle East & Africa Human Microbiome Market Outlook, By Autoimmune Disorder (2021-2030) ($MN)
Table 121 Middle East & Africa Human Microbiome Market Outlook, By Obesity (2021-2030) ($MN)
Table 122 Middle East & Africa Human Microbiome Market Outlook, By Other Types (2021-2030) ($MN)
Table 123 Middle East & Africa Human Microbiome Market Outlook, By Application (2021-2030) ($MN)
Table 124 Middle East & Africa Human Microbiome Market Outlook, By Diagnostics (2021-2030) ($MN)
Table 125 Middle East & Africa Human Microbiome Market Outlook, By Therapeutics (2021-2030) ($MN)
Table 126 Middle East & Africa Human Microbiome Market Outlook, By Other Applications (2021-2030) ($MN)

Product Code: SMRC24181

According to Stratistics MRC, the Global Human Microbiome Market is accounted for $0.8 billion in 2023 and is expected to reach $6.3 billion by 2030 growing at a CAGR of 34.1% during the forecast period. The term "Human Microbiomes Market" defines the area of biotechnology and healthcare that focuses on the thorough study, analysis, and commercial applications of the human microbiome, which is the enormous and diverse community of microorganisms that exists both inside and outside the human body. To comprehend the symbiotic interaction between the human body and its resident microorganisms, it comprises a variety of fields, including research, diagnostics, treatments, and customized medicine.

According to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Additionally, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040.

Market Dynamics:

Driver:

Research advances in the microbiome

An enormous shift has occurred in the comprehension of the human microbiome's involvement in human health and disease as a result of the substantial advancements made in the investigation of it over the past few decades. Additionally, the tremendous community of microorganisms that reside inside the human body has been thoroughly analyzed and characterized because of high-throughput sequencing methods and powerful bioinformatics tools.

Restraint:

Regulatory barriers

The lack of transparent and uniform regulatory processes for microbiome-based products and treatments is one of the main problems. The absence of simple and uniform regulatory frameworks for microbiome-based products and treatments may limit market expansion and increase entry hurdles. However, the variety of microbial communities and the dynamic nature of the human microbiome present difficulties for regulatory authorities when evaluating products' safety and efficacy.

Opportunity:

Chronic disease prevalence is on the rise

Globally, chronic illnesses such as obesity, diabetes, inflammatory bowel diseases, and autoimmune disorders are becoming more prevalent. As a result, in order to better understand and manage these chronic diseases, medical professionals and academics are exploring microbiome-based therapies. Additionally, the restoration of microbial equilibrium among individuals with chronic illnesses involves a number of developing methods, including probiotics, fecal microbiota transplantation (FMT), and microbiome regulation.

Threat:

Research and development expenses

In order to fully comprehend the complexity of the human microbiome as well as develop products and eliminates that are based on it, the field of microbiome research requires significant investments in research and development (R&D). The creation of microbiome therapies like probiotics and prebiotics, as well as data analysis, clinical trials, and microbiome sequencing, are all included in these expenditures. However, the variety of products and treatments available may be hampered by the high cost of R&D, which may prevent smaller businesses and startups from entering the market.

COVID-19 Impact:

Clinical trial research has been significantly hampered worldwide by the COVID-19 epidemic. Given that studies usually include poor people who are most in danger from COVID-19 exposure, this is very important. Similarly, COVID-19 has had a detrimental effect and might still have one on the operations of other companies, including their preclinical research and clinical testing of microbiome-based drugs and diagnostic instruments.

The probiotics segment is expected to be the largest during the forecast period

The segment for probiotics is anticipated to be the largest during the forecast period. Probiotics are living microorganisms that, when administered to a host in sufficient proportions, improve or maintain the host's overall health by restoring or maintaining their intestinal microbiome. Due to their significance in promoting immune health, boosting digestion, and potentially affecting a number of different elements of general wellbeing, they have grown tremendously popular. Furthermore, with an increasing emphasis on preventive health and wellness, the probiotics sector is anticipated to develop as customers look for microbiome-friendly remedies to their medical issues.

The diagnostics segment is expected to have the highest CAGR during the forecast period

Due to the growing awareness of the crucial role played by the human microbiome in health and illness, the diagnostics segment is anticipated to have the highest growth rate throughout the projection period. Microbiome diagnostics can offer a deeper comprehension of the microbial populations within the body due to developments in sequencing technologies and bioinformatics, enabling personalized and precise therapy. Moreover, microbiome diagnostics are also becoming more popular in healthcare due to their potential to support early disease detection, guide individualized treatment strategies, and assess the success of interventions.

Region with largest share:

North America held the largest share due to an established network of healthcare facilities, greater investment from major firms in developing more advanced technology, accelerating the process of creating new drugs, and a rise in research efforts in this field. Additionally, human microbiome treatments are getting more attention, lifestyle ailments are becoming more prevalent, and next-generation sequencing and the human microbiome are experiencing more technological advancements. These factors are all contributing to the market's growth in the region.

Region with highest CAGR:

Due to growing consumer interest in probiotics, prebiotics, and microbiome-focused products, the Asia-Pacific area is predicted to experience profitable growth. This is due to digestion, nutritional wellness, and the importance of the microbiome in overall well-being which are becoming more widely recognized. Additionally, the Asia Pacific area has experienced a rise in research and development activities in the field of microbiome science, especially in nations like China, Japan, and South Korea that have made significant investments in biotechnology and the life sciences.

Key players in the market

Some of the key players in Human Microbiome market include: Seres Therapeutics, Second Genome Inc., Osel Inc., Exeliom Biosciences SAS, Ginkgo Bioworks, Finch Therapeutics Group Inc., Evelo Biosciences Inc, DuPont, Axial Biotherapeutics, Inc. and Astarte Medical.

Key Developments:

In January 2023, Genetic Analysis AS, a research driven diagnostic company that focuses on innovative diagnostic solutions with microbiota analysis, entered into an agreement with Microbiome Research Pvt. Ltd., a India-based microbiome company, for launching a test service portfolio based on the GA-map Dysbiosis Test, and thus, making it the first CE-IVD marked standardized gut microbiome test.

In May 2022, 4D Pharma, a global pharmaceutical company that develops biotherapeutic products for diseases such as cancer, asthma, autism, and autoimmune conditions such as arthritis, announced clinical trial for MRx0518 with combination bavencio, a PD - L1 blocking antibody indicated for the treatment of urothelial cancer

Products Covered:

Medical Foods
Prebiotics
Probiotics
Symboitics
Other Products

Diseases Covered:

Metabolic
Endocrine
Infectious

Types Covered:

Cancer
Metabolic and Gastrointestinal Disorders
Autoimmune Disorder
Obesity
Other Types

Applications Covered:

Diagnostics
Therapeutics
Other Applications

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Human Microbiome Market, By Product

5.1 Introduction
5.2 Medical Foods
5.3 Prebiotics
5.4 Probiotics
5.5 Symboitics
5.6 Other Products

6 Global Human Microbiome Market, By Disease

6.1 Introduction
6.2 Metabolic
6.3 Endocrine
6.4 Infectious

7 Global Human Microbiome Market, By Type

7.1 Introduction
7.2 Cancer
7.3 Metabolic and Gastrointestinal Disorders
7.4 Autoimmune Disorder
7.5 Obesity
7.6 Other Types

8 Global Human Microbiome Market, By Application

8.1 Introduction
8.2 Diagnostics
8.3 Therapeutics
8.4 Other Applications

9 Global Human Microbiome Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Seres Therapeutics
11.2 Second Genome Inc.
11.3 Osel Inc.
11.4 Exeliom Biosciences SAS
11.5 Ginkgo Bioworks
11.6 Finch Therapeutics Group Inc.
11.7 Evelo Biosciences Inc
11.8 DuPont
11.9 Axial Biotherapeutics, Inc.
11.10 Astarte Medical